Sichenzia Ross Ference Kesner LLP Represents Immuron Limited on $6.1M IPO and NASDAQ listing


Press Release — New York, NY — June 14, 2017 — Sichenzia Ross Ference Kesner LLP (“SRFK”) announced today the Firm has represented Immuron Limited (NASDAQ: IMRN) (ASX : IMC), a clinical-stage biopharmaceutical company focused on NASH and OTC products, on the company’s U.S. underwritten public offering of American Depository Shares (ADSs) and warrants to purchase the company’s ADSs at a combined offering price of $10.00.

Each ADS represents 40 shares of the company’s ordinary shares. Immuron raised approximately $6,100,000 in gross proceeds, which will be used to advance their products, platform technologies, working capital, and general corporate purposes.

SRFK successfully advised the process by which Immuron listed its ADSs and warrants on NASDAQ under the symbols “NASDAQ:IMRN and IMRNW” respectively, which began trading on June 9, 2017.

The Sichenzia Ross  Ference Kesner LLP team was led by Partners Gregory Sichenzia, Darrin M. Ocasio, and David Manno.

Sichenzia Ross Ference LLP

Sichenzia Ross Ference LLP is a nationally recognized securities and corporate law firm that provides experienced representation in all matters involving the securities industry. Super Lawyers consistently recognizes our attorneys as among the highest rated securities lawyers in the nation. Our attorneys specialize in advising clients on private placements, initial (IPOs) and secondary public offerings, alternative public offerings, preparation of SEC filings and listings on major capital stock exchanges such as the NYSE (New York Stock Exchange), NASDAQ and OTC markets. In addition, our litigation and arbitration attorneys are highly skilled in representing clients from routine lawsuits to complex cases before the SEC, FINRA and other tribunals. We also represent clients in a range of residential and commercial real estate and trusts and estates matters.

Visit SRF's LinkedIn page
Sichenzia Ross Ference LLP